Training purpose selection is required.
Training plan selection is required.
Participants who complete this course will receive 1.0 P.A.C.E. Contact Hours. To receive P.A.C.E. Contact Hours you will need to register and complete the evaluation at the end of the training.
bioMérieux Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program
Instructions:
- Click the "Request" button.
- Create an account or click "Already Registered?" if you have an existing account.
- Select "View Transcript" and then click "Launch" course.
- When complete: Click Evaluate to complete the evaluation.
Your certificate is available under "My Transcript". Changing the "Active" drop-down to Completed courses.
Overview:
This course discusses that Multi-drug resistant (MDR) Gram-negative bacteria are an urgent, high priority threat worldwide due to few antibiotics available to treat such infection caused by these pathogens. Over the last decade, an ambitious development plan has led to the FDA approval of six new antibiotics with activity against specific MDR Gram-negative bacteria, with two additional promising agents targeted for approval by 2020. This program will review these new antibiotics, focusing on their microbiological spectrum of activity and role in clinical practice.
Objectives:
At the end of this session, you will be able to:
- List eight new antibiotics targeting resistant Gram-negative bacteria approved (or soon to be) after 2010
- Describe microbiological spectrum of activity, available methods for susceptibility testing, and differentiate coverage based on phenotypic and genotypic profiles
- Identify appropriate clinical scenarios for these new antibiotics
Speaker:
Dr. Joseph L. Kuti, Pharm.D., FIDP
Associate Director, Clinical and Economic Studies
Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, Connecticut USA
Developed by: bioMérieux Learning and Development Department
Level of Instruction: Intermediate
Let's get started!